血清3-磷酸甘油醛脱氢酶抗体水平在视神经脊髓炎谱系疾病中的变化及其临床意义

Changes of serum glyceraldehyde-3-phosphate dehydrogenase antibody level in optic nerve myelomyelitis and its clinical significance

目的研究视神经脊髓炎谱系疾病(NMOSD)患者血清中3-磷酸甘油醛脱氢酶(GAPDH)抗体的水平变化及其临床意义。方法收集符合纳入标准的NMOSD患者和正常对照组的血清,检测血清中GAPDH抗体水平,并分析其与NMOSD分期、分型、血清水通道蛋白4(AQP4)抗体状态和临床特点的关系。结果血清GAPDH抗体水平在NMOSD组显著高于正常对照组(P<0.05);急性期明显高于缓解期和正常对照组(均P<0.05),缓解期与正常对照组差异无统计学意义(均P>0.05)。AQP4-IgG(+)组与AQP4-IgG(-)组差异无统计学意义(P>0.05),AQP4-IgG(+)组与正常对照组相比,差异无统计学意义(P>0.05),AQP4-IgG(-)组明显高于正常对照组(P<0.05)。结论NMOSD患者急性期血清GAPDH抗体水平明显升高,GAPDH抗体参与了NMOSD患者脱髓鞘的重要环节并与NMOSD的活动性密切相关;GAPDH抗体在AQP4-IgG(-)组中明显升高,说明GAPDH抗体可能在AQP4-IgG(-)的NMOSD患者中作为一种轴突自身免疫性抗原而发挥作用。

Objective To study the changes of serum glyceraldehyde-3-phosphate dehydrogenase(GAPDH)antibody level in patients with neuromyelitis lineage disease(NMOSD)and its clinical significance.Methods Serum of NMOSD patients and normal control group meeting the inclusion criteria were collected to detect the serum level of GAPDH antibody and analyze its relationship with NMOSD staging,typing,Aquaporin-4(AQP4)antibody status and clinical characteristics.Results Serum GAPDH antibody level in NMOSD group was significantly higher than that in normal control group(P<0.05);the level in the acute phase was significantly higher than that in the remission phase and normal control group(all P<0.05),there was no significant difference between the remission stage and the normal control group(P>0.05).There was no significant difference between AQP4-IgG(+)group and AQP4-IgG(-)group(P>0.05),AQP4-IgG(+)group had no significant difference compared with the normal control group(P>0.05),AQP4-IgG(-)group was significantly higher than the normal control group(P<0.05)Conclusions Serum GAPDH antibody level was significantly increased in the acute phase of NMOSD patients.GAPDH antibody is involved in the important link of demyelination in NMOSD patients and is closely related to the activity of NMOSD.GAPDH antibody was significantly increased in the AQP4-IgG(-)group,indicating that GAPDH antibody may play a role as an axonal autoimmune antigen in AQP4-IgG(-)NMOSD patients.